Evidence map›Paper›PMID 22829804›Full record

ReviewExperimental diabetes research2012

The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.

Rebecca Hutcheson, Petra Rocic

2 registry-linked trialsOpen access · hybridFull text readReview
In one paragraph

Review in Experimental diabetes research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02695186 unknown statusnot on this mapstarted 2016, after this paper: background citation

Markers of Oxidative Stress and Inflammation in Patients With Intestinal Metaplasia and Metabolic Syndrome

TypeobservationalSponsorGeneral Hospital of FiliatesRan2016 to 2016Enrolled180ConditionsIntestinal Metaplasia, Metabolic Syndrome, Oxidative Stress, Inflammatory ResponseArmsGastroscopy
NCT06105060 early_phase1completednot on this mapstarted 2023, after this paper: background citation

Clinical and Biochemical Study of the Effects of Rosuvastatin, Vitamin E, and N-Acetyl Cysteine on Patients With Non-alcoholic Steatohepatitis: a Randomized Controlled Trial

TypeinterventionalSponsorBeni-Suef UniversityRan2023 to 2024Enrolled175ConditionsNon-alcoholic SteatohepatitisArmsRosuvastatin 20mg
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 199 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Personal exposure of PMEnvironmental science and pollution research international · 2023
    Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rebecca HutchesonDepartment of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, 307 North University Boulevard, Mobile, AL 36688, USA.
Petra Rocic
University of South Alabama · US

Funding

Regulation of Coronary Collateral Growth in the Metabolic SyndromeR01HL093052 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI ROCIC, PETRA · 2008 to 2018
$3.7M
NHLBI NIH HHS R01 HL093052
6 · The paper itself

Abstract

The metabolic syndrome affects 30% of the US population with increasing prevalence. In this paper, we explore the relationship between the metabolic syndrome and the incidence and severity of cardiovascular disease in general and coronary artery disease (CAD) in particular. Furthermore, we look at the impact of metabolic syndrome on outcomes of coronary revascularization therapies including CABG, PTCA, and coronary collateral development. We also examine the association between the metabolic syndrome and its individual component pathologies and oxidative stress. Related, we explore the interaction between the main external sources of oxidative stress, cigarette smoke and air pollution, and metabolic syndrome and the effect of this interaction on CAD. We discuss the apparent lack of positive effect of antioxidants on cardiovascular outcomes in large clinical trials with emphasis on some of the limitations of these trials. Finally, we present evidence for successful use of antioxidant properties of pharmacological agents, including metformin, statins, angiotensin II type I receptor blockers (ARBs), and angiotensin II converting enzyme (ACE) inhibitors, for prevention and treatment of the cardiovascular complications of the metabolic syndrome.

Indexed as

Oxidative StressAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAnimalsAntioxidantsCardiovascular DiseasesCoronary Artery DiseaseHumansInsulin ResistanceMetabolic SyndromeMetforminMiceObesityRisk FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAntioxidantsMetformin

Identifiers

PMID22829804
PMCPMC3399393
OpenAlexW2098417455

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.